A newly discovered family of proline-rich antimicrobial peptides called rumicidins, found in ruminant mammals, kill bacteria by plugging the ribosome exit tunnel and showed broad-spectrum antibacterial activity with efficacy in animal infection models and no toxicity to human cells.
Broad-spectrum activity with in vivo efficacy and no human cell toxicityRumicidins achieved the rare combination of killing bacteria across species, working in live animal infection models, and showing no adverse effects on human cells — key criteria for antibiotic drug candidates
What the researchers found
Genome mining revealed rumicidin genes widespread among ruminant mammals. The peptides belong to the proline-rich cathelicidin family and kill bacteria by inhibiting the elongation stage of translation (protein synthesis).
Cryo-EM structural analysis of the E. coli 70S ribosome bound to a rumicidin revealed that the peptide spans the ribosomal A-site cleft and plugs into the nascent peptide exit tunnel, interacting with its constriction point via a conserved Trp23-Phe24 dyad. Bacterial resistance mechanisms involve knockout of the SbmA transporter (needed for peptide uptake) or modification of the MacAB-TolC efflux pump. The peptides demonstrated broad-spectrum antibacterial activity, efficacy in an animal infection model, and no adverse effects on human cells in vitro.
Why it matters
The antimicrobial resistance crisis demands new antibiotics with novel mechanisms of action. Rumicidins represent a new antibiotic class that works by a well-defined structural mechanism — plugging the ribosome exit tunnel — which is distinct from most existing antibiotics. The combination of broad-spectrum activity, in vivo efficacy, lack of human cell toxicity, and atomic-resolution structural data makes them unusually complete candidates for antibiotic development. Published in Nature Communications, this represents a high-impact discovery in the antimicrobial peptide field.
How the study worked
The researchers used genome mining to identify rumicidin genes across ruminant genomes. Peptides were produced and tested biochemically for translation inhibition using in vitro translation assays. The structural mechanism was determined by cryo-electron microscopy of the E. coli 70S ribosome-rumicidin complex. Antibacterial spectrum was assessed through standard susceptibility testing against multiple bacterial species. In vivo efficacy was tested in an animal infection model. Cytotoxicity to human cells was evaluated in vitro. Resistance mechanisms were characterized using bacterial knockout mutants.
What this study cannot tell us
While in vivo efficacy was demonstrated in an animal infection model, the specific model, dosing, and bacterial challenge details were not provided in the abstract. The SbmA transporter-dependent uptake pathway is a known vulnerability of PrAMPs — bacteria can develop resistance by losing this transporter. The identified efflux pump modification represents another resistance concern. Human pharmacokinetics, stability, and potential immunogenicity of these peptides in therapeutic use remain unknown. Translation from animal-derived peptides to human therapeutics requires extensive optimization.
How to read the evidence
This is a comprehensive discovery paper published in Nature Communications combining genomics, biochemistry, structural biology (cryo-EM), microbiology, and in vivo testing. The multi-method approach provides strong mechanistic and preclinical evidence, though the study represents early-stage drug discovery without clinical data.
When this study was published
Published in 2024, this is a very recent discovery reflecting cutting-edge approaches (genome mining, cryo-EM) in antimicrobial peptide research.
The bigger picture
Proline-rich antimicrobial peptides (PrAMPs) that target bacterial ribosomes have attracted increasing attention as potential antibiotics because they exploit a target (the ribosome) that is essential and highly conserved across bacteria but structurally distinct from human ribosomes. This study extends the known diversity of ribosome-targeting PrAMPs beyond previously characterized families (like apidaecins from insects) to ruminant mammals, demonstrating that evolution has independently arrived at this antimicrobial strategy across very different animal lineages. The structural precision of the cryo-EM data enables rational drug design based on the rumicidin scaffold.
Questions still open
- Can the rumicidin scaffold be modified to overcome SbmA-independent uptake resistance while retaining ribosome-targeting activity?
- How does the spectrum of activity compare to other ribosome-targeting PrAMPs like oncocin or apidaecin, and could combinations enhance coverage?
- Do ruminant animals naturally use rumicidins against specific gut or respiratory pathogens, and does this provide ecological insights for antibiotic application?
Common questions
What are rumicidins and how were they discovered?
How do rumicidins kill bacteria differently from existing antibiotics?
Read the original research
Rumicidins are a family of mammalian host-defense peptides plugging the 70S ribosome exit tunnel.
Nature communications, 15(1), 8925
Citation
Panteleev, Pavel V; Pichkur, Eugene B; Kruglikov, Roman N; Paleskava, Alena; Shulenina, Olga V; Bolosov, Ilia A; Bogdanov, Ivan V; Safronova, Victoria N; Balandin, Sergey V; Marina, Valeriya I; Kombarova, Tatiana I; Korobova, Olga V; Shamova, Olga V; Myasnikov, Alexander G; Borzilov, Alexander I; Osterman, Ilya A; Sergiev, Petr V; Bogdanov, Alexey A; Dontsova, Olga A; Konevega, Andrey L; Ovchinnikova, Tatiana V. (2024). Rumicidins are a family of mammalian host-defense peptides plugging the 70S ribosome exit tunnel.. Nature communications, 15(1), 8925. https://doi.org/10.1038/s41467-024-53309-y